Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Adrenomedullin vs Intermedin (Adrenomedullin-2) — Peptide Comparison

At a Glance Quickcomparison Dose Range Adrenomedullin As prescribed–As prescribed mg Intermedin (Adrenomedullin-2) Frequency Once daily Administration Intravenous infusion As directed by healthcare provider Cycle Length Ongoing/indefinite Onset Speed Moderate

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Adrenomedullin

As prescribed–As prescribed mg

Intermedin (Adrenomedullin-2)

Frequency

Once daily

Administration

Intravenous infusion

As directed by healthcare provider

Cycle Length

Ongoing/indefinite

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Moderate human trials (Phase 1-2)

Limited human trials

Efficacy

Benefitratings

Cardiovascular Support

Tissue Protection

Immune Function

Cardiovascular Health & Protection

Stress & Anxiety Management

Anti-Inflammatory & Antioxidant Support

Technical Data

Compoundspecifications

Molecular Formula

C264H406N80O77S3

Molecular Weight

6029 Da (Daltons)

Half-Life

Approximately 20-30 minutes in plasma (rapid metabolism)

Bioavailability

Parenteral administration only; peptide undergoes proteolytic cleavage in circulation

CAS Number

148498-78-6

C15H25NO5 (precursor compound)

299.36 g/mol (precursor)

Approximately 2-6 hours (varies by route of administration)

Varies by route of administration

Protocols

Dosingtiers

starting

5 ng/kg/min

Continuous infusion, 8 hours per day

14 days (trial protocol)

Adrenomedullin is given as a slow drip into a vein in clinical trials, not by self-injection. This low dose was the bottom step tested for steroid-resistant ulcerative colitis. [4]

standard

10 ng/kg/min

Middle dose tested in the ulcerative colitis trial. [4]

advanced

15 ng/kg/min

This higher dose was the only one that significantly improved disease scores in the trial. The same 15 ng/kg/min rate was also tested safely in healthy volunteers. [4][5]

Applications

Bestsuited for

Cardiovascular health optimization

Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Maintaining healthy blood pressure

Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Recovery from illness or sepsis

Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tissue protection and oxygen delivery

Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting cardiovascular health and heart function

Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing inflammation and oxidative stress

Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Improving overall vascular health and circulation

Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Mild discomfort at treatment site

Excessive blood pressure lowering (hypotension)

Headaches (from pressure changes)

Flushing and mild facial redness

Dizziness or lightheadedness

Mild electrolyte shifts

Localized injection site reactions

Increased urination (natriuretic effect)

Serious

Severe allergic reaction

Mild headache

Injection site reactions (redness, itching, swelling)

Nausea or mild gastrointestinal discomfort

Fatigue or mild energy changes

Transient hypotension (temporary low blood pressure)

Mild palpitations (in some individuals)

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses.

Contraindications

xSevere hypotension or shock states

xConcurrent use with certain vasopressor medications

xPregnancy and breastfeeding

xSevere kidney or liver dysfunction

Not FDA approved

Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts.

xPregnancy and breastfeeding - insufficient safety data

xActive cardiovascular events (heart attack, stroke)

xSevere renal (kidney) impairment

xHypersensitivity to calcitonin family peptides

xUncontrolled endocrine disorders

Decision Guide

Which isright for you?

Choose Adrenomedullin if...

Cardiovascular health optimization

Maintaining healthy blood pressure

Recovery from illness or sepsis

Tissue protection and oxygen delivery

Choose Intermedin (Adrenomedullin-2) if...

Supporting cardiovascular health and heart function

Managing inflammation and oxidative stress

Improving overall vascular health and circulation

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status Research compound Safety Overview Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods. Contraindications xActive thymic tumors or malignancies xKnown hypersensitivity to animal-derived peptide products xPregnancy and breastfeeding (insufficient safety data) xSevere uncontrolled autoimmune disease without medical supervision Thymopentin is well-tolerated with minimal side effects reported in clinical trials. Most adverse events are mild and local. No serious safety concerns have emerged from decades of clinical use in China and Europe. xPregnancy and breastfeeding xActive malignancy (without medical supervision) xSevere immunosuppression xHypersensitivity to peptide medications Decision Guide

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →